Clinical Trials Directory

Trials / Completed

CompletedNCT00832897

Evaluation of Topical Riboflavin Exposed to UVA Radiation and Implantation of Corneal Ring

"Evaluation of Topical Riboflavin Exposed to UVA Radiation and Implantation of Intrastromal Corneal Ring for Treatment of Keratoconus and Others Irregulars Astigmatisms."

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
31 (actual)
Sponsor
Federal University of São Paulo · Academic / Other
Sex
All
Age
Healthy volunteers
Accepted

Summary

The purpose of this study is to postpone the corneal transplantation in keratoconus and promote the stiffness of the cornea across the riboflavin-UVA corneal collagen crosslinking , and after, corneal ring surgery.

Detailed description

Keratoconus is a progressive disease where cornea is thin and has a higher curvature.In early conditions, it may be corrected by glasses or contact lens.When these possibilities are not more possibles, it may be corrected by corneal ring surgery ore corneal transplantation depending your degree. In this study, the patients with a degree of keratoconus on I or II, will be submitted to corneal collagen crosslinking and then a corneal ring surgery. The corneal collagen crosslinking promote the stiffness of the cornea across the riboflavin-UVA irradiation, avoid the progression of the keratoconus.After three months of crosslinking, these patients will be submitted a corneal ring surgery. These patients will be allowed by two years and various exams will realized them.

Conditions

Interventions

TypeNameDescription
PROCEDURECorneal collagen crosslinkingThe patients will be submitted to corneal collagen crosslinking, that consists: Instillation of riboflavin eyedrop in the cornea for thirty minutes, and after, the patient will stay under the Crosslinking equipment, for more thirty minutes, also receiving riboflavin eyedrop.

Timeline

Start date
2008-03-01
Primary completion
2008-11-01
Completion
2010-10-01
First posted
2009-01-30
Last updated
2011-01-07

Locations

1 site across 1 country: Brazil

Source: ClinicalTrials.gov record NCT00832897. Inclusion in this directory is not an endorsement.